Johnson & Johnson CFO Joe Wolk says the company is well positioned for a strong 2026 and discusses plans to spin off its slower-growing orthopedics business and the outlook for drug pricing on "Bloomberg Open Interest." J&J announced third-quarter sales and earnings that modestly beat expectations, and raised revenue guidance for the full year. ...

公司业绩与股价表现 - 公司公布超预期并上调指引的财报后 股价上涨并接近历史最高纪录 [1] - 公司宣布计划分拆其骨科业务 [1]